New diabetes drug to launch in June

The U.S. FDA has approved Byetta, known generically as exenatide, to be used in combination with other oral drugs for those with Type 2 diabetes who are not yet dependent on insulin. The drug, a synthetic version of the saliva protein of a Gila monster, is injected twice a day and is designed to stimulate insulin production only when needed by the body. Eli Lilly and Amylin Pharmaceuticals are co-developers of the drug and will co-market it.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX